Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rang in aandelen #27036
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aandeelprijs
$1.48
Laatst gesynchroniseerd: 2023-05-31
Marktkapitalisatie
$35.54M
Verandering (1 dag)
-5.73%
Verandering (1 jaar)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Categorie

Koersgeschiedenis voor TCR2 Therapeutics Inc. (TCRR)
Hoogste slotkoers: $1.83 op 2023-05-01

Laagste slotkoers: $16.51 op 2019-02-01
Koersgeschiedenis van TCR2 Therapeutics Inc. van 2019 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$758.75 6.61%
CH